Abstract
Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes). However, assessing sudden death (SD) risk and identifying the most appropriate candidates for prophylactic device therapy is a complex process compounded by the unpredictability of the underlying arrhythmogenic substrate, absence of a single dominant and quantitative risk maker for this heterogeneous disease, and also the difficulty encountered in assembling sufficiently powered prospective and randomized trials in large patient populations. Patients with multiple risk factors and most young patients with one strong and unequivocal risk marker can be considered candidates for primary prevention defibrillators. Despite certain limitations, the current risk factor algorithm (when combined with a measure of individual physician judgment) has proved to be an effective strategy for targeting high-risk status. This approach has served the HCM patient population well, as evidenced by the significant appropriate defibrillator intervention rates, although a very small proportion of patients without conventional risk factors may also be at risk for SD. Indeed, the introduction of implantable defibrillators to the HCM patient population represents a new paradigm for clinical practice, offering the only proven protection against SD by virtue of effectively terminating ventricular tachycardia/fibrillation. In the process, implantable defibrillators have altered the natural history of HCM, potentially providing the opportunity of normal or near-normal longevity for many patients. Prevention of SD is now an integral, albeit challenging, component of HCM management.
Similar content being viewed by others
References
Braunwald, E., Lambrew, C. T., Rockoff, S. D., et al. (1964). Idiopathic hypertrophic subaortic stenosis. I: A description of the disease based upon an analysis of 64 patients. Circulation, 30(suppl IV), 3–217.
Maron, B. J. (2002). Hypertrophic cardiomyopathy: A systematic review. JAMA, 287, 1308–1320.
Maron, B. J., McKenna, W. J., Danielson, G. K., et al. (2003). American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Journal of the American College of Cardiology, 42, 1687–1713.
Maron, B. J., Towbin, J. A., Thiene, G., et al. (2006). Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807–1816.
Spirito, P., Seidman, C. E., McKenna, W. J., et al. (1997). The management of hypertrophic cardiomyopathy. New England Journal of Medicine, 336, 775–785.
Wigle, E. D., Rakowski, H., Kimball, B. P., et al. (1996). Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation, 92, 1680–1692.
Klues, H. G., Schiffers, A., & Maron, B. J. (1995). Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. Journal of the American College of Cardiology, 26, 1699–1708.
Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., et al. (2009). Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Journal of the American College of Cardiology, 54, 220–228.
Maron, B. J., Gardin, J. M., Flack, J. M., et al. (1995). Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation, 92, 785–789.
Maron, M. S., Olivotto, I., Betocchi, S., et al. (2003). Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. New England Journal of Medicine, 348, 295–303.
Maron, M. S., Olivotto, I., Zenovich, A. G., et al. (2006). Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation, 114, 2232–2239.
Cecchi, F., Olivotto, I., Gistri, R., et al. (2003). Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. New England Journal of Medicine, 349, 1027–1035.
Maron, B. J., Shen, W. K., Link, M. S., Epstein, A. E., Almquist, A. K., et al. (2000). Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 365–373.
Maron, B. J., Spirito, P., Shen, W.-K., Haas, T. S., Formisano, F., Link, M. S., et al. (2007). Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA, 298, 405–412.
Maron, B. J., & Spirito, P. (2008). Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 19, 1118–1126.
Seidman, J. G., & Seidman, C. E. (2001). The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell, 104, 557–567.
Alcalai, R., Seidman, J. G., & Seidman, C. E. (2008). Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics. Journal of Cardiovascular Electrophysiology, 19, 104–110.
Bos, J. M., Towbin, J. A., & Ackerman, M. J. (2009). Diagnostic, prognostic, and therapeutic implications of gene testing for hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 54, 201–211.
Maron, B. J. (2003). Sudden death in young athletes. New England Journal of Medicine, 349, 1064–1075.
Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009). Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the U.S., 1980–2006. Circulation, 119, 1085–1092.
Spirito, P., Bellone, P., Harris, K. M., et al. (2000). Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 1778–1785.
Maki, S., Ikeda, H., Muro, A., et al. (1998). Predictors of sudden cardiac death in hypertrophic cardiomyopathy. American Journal of Cardiology, 82, 774–778.
Maron, B. J., Piccininno, M., Casey, S. A., et al. (2003). Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. American Journal of Cardiology, 91, 626–628.
Maron, B. J., Olivotto, I., Spirito, P., Casey, S. A., Bellone, P., Gohman, T. G., et al. (2000). Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patient population. Circulation, 102, 858–864.
Elliott, P. M., Poloniecki, J., Dickie, S., Sharma, S., Monserrat, L., Varnava, A., et al. (2000). Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. Journal of the American College of Cardiology, 36, 2212–2218.
Elliott, P. M., Gimeno-Blanes, J. R., Mahon, N. G., Poloniecki, J. D., & McKenna, W. J. (2001). Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, 357, 420–424.
Maron, B. J., Estes, N. A. M., III, Maron, M. S., Almquist, A. K., Link, M. S., & Udelson, J. (2003). Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation, 107, 2872–2875.
Maron, B. J., Casey, S. A., Poliac, L. C., Gohman, T. E., Almquist, A. K., & Aeppli, D. M. (1999). Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA, 281, 650–655.
Maron, B. J., Casey, S. A., Hauser, R. G., et al. (2003). Clinical course of hypertrophic cardiomyopathy with survival to advanced ages. Journal of the American College of Cardiology, 42, 882–888.
Brock, R. (1957). Functional obstruction of left ventricle (acquired aortic subvalvular stenosis). Guy's Hospital Reports, 106, 221–238.
Teare, D. (1958). Asymmetrical hypertrophy of the heart in young athletes. British Heart Journal, 20, 1–8.
Maron, B. J. (2004). Hypertrophic cardiomyopathy: An important global disease. American Journal of Medicine, 116, 63–65. (Editorial).
Zou, Y., Song, L., Wang, Z., et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults. American Journal of Medicine, 115, 14–18.
Maron, B. J., Peterson, E. E., Maron, M. S., & Peterson, J. E. (1994). Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. American Journal of Cardiology, 73, 577–580.
Maron, B. J., Carney, K. P., Lever, H. M., et al. (2003). Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 41, 974–980.
Maron, B. J., & Roberts, W. C. (1979). Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation, 59, 689–706.
Maron, B. J., Anan, T. J., & Roberts, W. C. (1981). Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation, 63, 882–894.
Maron, B. J., Wolfson, J. K., Epstein, S. E., & Roberts, W. C. (1986). Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 8, 545–557.
Maron, B. J., & Zipes, D. P. (2005). 36th Bethesda Conference: Eligibility recommendations for competitive athletes with cardiovascular abnormalities. Journal of the American College of Cardiology, 45, 1312–1375.
Pelliccia, A., Fagard, R., Bjornstad, H. H., et al. (2005). Recommendations for competitive sports participation in athletes with cardiovascular disease. European Heart Journal, 14, 1422–1445.
Spirito, P., Autore, C., Rapezzi, C., Bernabo, P., Badagliacca, R., Maron, M. S., et al. (2009). Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation, 119, 1703–1710.
Nishimura, R. A., & Ommen, S. R. (2007). Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: How low the bar? JAMA, 298, 452–454. (Editorial).
Monserrat, L., Elliott, P. M., Gimeno, J. R., et al. (2003). Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. Journal of the American College of Cardiology, 42, 873–879.
Olivotto, I., Maron, B. J., Montereggi, A., et al. (1999). Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 33, 2044–2051.
Adabag, A. S., Casey, S. A., Kuskowski, M. A., et al. (2005). Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 45, 697–704.
Adabag, A. S., & Maron, B. J. (2007). Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy. Annals of Noninvasive Electrocardiology, 12, 171–180.
McKenna, W. J., & Behr, E. R. (2002). Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death. Heart, 87, 169–176.
Maron, B. J., Savage, D. D., Wolfson, J. K., & Epstein, S. E. (1981). Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. American Journal of Cardiology, 48, 252–257.
Maron, M. S., Finley, J. J., Bos, J. M., Hauser, R. H., Manning, W. J., Haas, T. S., et al. (2008). Prevalence, clinical significance and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation, 118, 1541–1549.
Harris, K. M., Spirito, P., Maron, M. S., et al. (2006). Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation, 114, 216–225.
van der Lee, C., ten Cate, F. J., Geleijnse, M. L., et al. (2005). Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation, 112, 482–488.
Sorajja, P., Valeti, U., Nishimura, R., Ommen, S. R., Rihal, C. S., Gersh, B. J., et al. (2008). Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation, 118, 131–139.
Alam, M., Dokainish, H., & Lakkis, N. (2006). Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. Journal of Interventional Cardiology, 19, 319–327.
Kimmelstiel, C. D., & Maron, B. J. (2004). Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation, 109, 452–456.
Maron, B. J. (2007). Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation, 116, 196–206.
Batalis, N. I., Harley, R. A., & Collins, K. A. (2005). Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: Case reports and an approach to the autopsy and death certification. American Journal of Forensic Medicine and Pathology, 26, 343–348.
Hori, Y., Ueda, M., Nakayama, T., Saegusa, N., Uehara, M., Lee, K., et al. (2007). Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology, 119, 403–407.
Raute-Kreinsen, U. (2003). Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathology, Research and Practice, 1999, 121–127.
Simon, R. D., Crawford, F. A., 3rd, Spencer, W. H., 3rd, & Gold, M. R. (2005). Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing and Clinical Electrophysiology, 28, 1354–1356.
Boltwood, C. M., Jr., Chien, W., & Ports, T. (2004). Ventricular tachycardia complicating alcohol septal ablation. New England Journal of Medicine, 351, 1914–1915.
Maron, B. J. (2000). Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet, 355, 425–426. (Editorial).
van Dockum, W. G., ten Cate, F. J., ten Berg, J. M., Beek, A. M., Twisk, J. W., Vos, J., et al. (2004). Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Evaluation by contrast-enhanced magnetic resonance imaging. Journal of the American College of Cardiology, 43, 27–34.
Valeti, U. S., Nishimura, R. A., Holmes, D. R., Araoz, P. A., Glockner, J. F., Breen, J. F., et al. (2007). Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 49, 350–357.
Noseworthy, P. A., Rosenberg, M. A., Fifer, M. A., Palacios, I. F., Lowry, P. A., Ruskin, J. N., et al. (2009). Ventricular arrhythmia following alcohol ablation for obstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 104, 128–132.
Cuoco, F. A., Spencer, W. H., III, Fernandes, V. L., Nielsen, C. D., Nagueh, S., Sturdivant, J. L., et al. (2008). Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 52, 1718–1723.
Gilligan, D. M., Chan, W. L., Ang, E. L., & Oakley, C. M. (1991). Effects of a meal on hemodynamic function at rest and during exercise in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 18, 429–436.
Sorajja, P., Ommen, S. R., Nishimura, R. A., Gersh, B. J., Berger, P. B., & Tajik, A. J. (2003). Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation, 108, 2342–2348.
Olivotto, I., Cecchi, F., Casey, S. A., Dolara, A., Traverse, J. H., & Maron, B. J. (2001). Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation, 104, 2517–2524.
Watkins, H., Rosenzweig, A., Hwang, D. S., Levi, T., McKenna, W., Seidman, C. E., et al. (1992). Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. New England Journal of Medicine, 326, 1108–1114.
Ackerman, M. J., Van Driest, S. L., Ommen, S. R., et al. (2002). Prevalence and age dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: A comprehensive outpatient perspective. Journal of the American College of Cardiology, 39, 2042–2048.
Van Driest, S. L., Ackerman, M. J., Ommen, S. R., et al. (2002). Prevalence and severity of “benign” mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation, 106, 3085–3090.
Maron, B. J., Roberts, W. C., Arad, M., Haas, T. S., Spirito, P., Wright, G. B., et al. (2009). Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA, 301, 1253–1259.
Kelly, M., & Semsarian, C. (2009). Multiple mutations in genetic cardiovascular disease: A marker of disease severity? Circulation: Cardiovascular Genetics, 2, 182–190.
Saumarez, R. C., Pytkowski, M., Sterlinski, M., et al. (2008). Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. European Heart Journal, 29, 1653–1661.
Basso, C., Thiene, G., Mackey-Bojack, S., Frigo, A. C., Corrado, D., & Maron, B. J. (2009). Myocardial bridging: A frequent component of the hypertrophic cardiomyopathy phenotype lacks systematic association with sudden cardiac death. European Heart Journal, 30, 1627–1634.
Montgomery, J. V., Harris, K. M., Casey, S. A., et al. (2005). Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. American Journal of Cardiology, 96, 270–275.
McLoed, C. J., Ackerman, M. J., Nishimura, R. A., et al. (2009). Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. Journal of the American College of Cardiology, 54, 229–233.
Maron, M. S., Olivotto, I., Maron, B. J., Prasad, S. K., Cecchi, F., Udelson, J. E., et al. (2009). The case for myocardial ischemia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 54, 866–875.
Maron, M. S., Appelbaum, E., Harrigan, C., Buros, J., Gibson, M., Hanna, C. A., et al. (2008). Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circulation: Heart Failure, 1, 184–191.
Adabag, A. S., Maron, B. J., Appelbaum, E., Harrigan, C. J., Buros, J. L., Gibson, C. M., et al. (2008). Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. Journal of the American College of Cardiology, 51, 1369–1374.
Maron, B. J., Maron, M. S., Lesser, J. R., Hauser, R. G., Haas, T. S., Harrigan, C. T., et al. (2008). Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. American Journal of Cardiology, 101, 544–547.
Melacini, P., Maron, B. J., Bobbo, F., et al. (2007). Evidence that pharmacological strategies lack efficacy for the prevention for sudden death in hypertrophic cardiomyopathy. Heart, 93, 708–710.
Mirowski, M., Reid, P. R., Mower, M. M., Watkins, L., Gott, V. L., Schauble, J. F., et al. (1980). Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. New England Journal of Medicine, 303, 322–324.
Jayatilleke, I., Doolan, A., Ingles, J., et al. (2004). Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. American Journal of Cardiology, 93, 1192–1194.
Woo, A., Monakier, D., Harris, L., et al. (2007). Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart, 93, 1044–1045.
Maron, B. J., Semsarian, C., Shen, W. K., Link, M. S., Epstein, A. E., Estes, N. A. M., III, et al. (2009). Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm, 6, 599–602.
Kiernan, T. J., Weivoda, P. L., Somers, V. K., Ommen, S. R., & Gersh, B. J. (2008). Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy. Pacing and Clinical Electrophysiology, 31, 1253–1258.
Hauser, R. G., & Maron, B. J. (2005). Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation, 112, 2040–2042.
Almquist, A. K., Hanna, C. A., Haas, T. S., & Maron, B. J. (2008). Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 19, 319–322.
Lin, G., Nishimura, R. A., Gersh, B. J., Ommen, S., Ackerman, M., & Brady, P. A. (2009). Device complications and inappropriate implantable cardioverter-defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart, 95, 709–714.
Sherrid, M. V., & Daubert, J. P. (2008). Risks and challenges of implantable cardioverter-defibrillators in young adults. Progress in Cardiovascular Diseases, 51, 237–263.
Almquist, A. K., Montgomery, J. V., Haas, T. S., & Maron, B. J. (2005). Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm, 2, 814–819.
You, J. J., Woo, A., Ko, D. T., Dameron, D. A., Mihailovic, A., & Krahn, M. (2007). Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. American Heart Journal, 154, 899–907.
Goldenberg, I., Moss, A. M., Maron, B. J., Dick, A. W., & Zareba, W. (2005). Cost effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Annals of Noninvasive Electrocardiology, 10(Suppl. 4), 67–83.
Camm, A., & Nisam, S. (2000). The utilization of the implantable defibrillator—A European enigma. European Heart Journal, 21, 1998–2004.
Acknowledgements
This study was supported in part by a grant from The Hearst Foundations, New York, NY, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maron, B.J. Sudden Death in Hypertrophic Cardiomyopathy. J. of Cardiovasc. Trans. Res. 2, 368–380 (2009). https://doi.org/10.1007/s12265-009-9147-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-009-9147-0